This conference will draw experts in O-GlcNAc biology from around the world to discuss how O-GlcNAc and O-GlcNAc cycling enzymes modulate protein function in basic biological processes as well as in disease states, including diabetes, cancer, cardiovascular disease and neurological diseases.
Our Head of Translational Medicine Dr Ryan Schubert will present “Human pharmacology highlights the potential of the ASN51 as an ideal once-a-day oral drug for the treatment of neurodegenerative diseases” at the session “O-GlcNAcylation and neuronal functions and disease” scheduled from 9:00 am to 12:00 am on Sunday, July 10th.
Our Head of Preclinical Development Dr Bruno Permanne will present a poster “ASN51, an Orally Bioavailable Small-molecule O-GlcNAcase Inhibitor, has both immediate and Disease-Modifying Benefits in Preclinical Models of Parkinson’s Disease”.
Asceneuron is proud to support this event as a sponsor in its commitment to advancing and promoting research on O-GlcNAc biology to find novel treatments for numerous human diseases.
Further information about the event can be found here.